Cladribine and ocrelizumab induce differential miRNA profiles in peripheral blood mononucleated cells from relapsing–remitting multiple sclerosis patients

Background and objectivesMultiple sclerosis (MS) is a chronic, progressive neurological disease characterized by early-stage neuroinflammation, neurodegeneration, and demyelination that involves a spectrum of heterogeneous clinical manifestations in terms of disease course and response to therapy. E...

詳細記述

書誌詳細

主要な著者:	Ivan Arisi, Leonardo Malimpensa, Valeria Manzini, Rossella Brandi, Tommaso Gosetti di Sturmeck, Chiara D’Amelio, Sebastiano Crisafulli, Gina Ferrazzano, Daniele Belvisi, Francesca Malerba, Rita Florio, Esterina Pascale, Hermona Soreq, Marco Salvetti, Antonino Cattaneo, Mara D’Onofrio, Antonella Conte
フォーマット:	Artigo
言語:	Inglês
出版事項:	Frontiers Media S.A. 2023-12-01
シリーズ:	Frontiers in Immunology
主題:	multiple sclerosis cladribine ocrelizumab DMT biomarker miRNA
オンライン･アクセス:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1234869/full
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!